PinPoint Get PinPoint on the App Store

Peptides / Compound guide

Tesamorelin guide

Tesamorelin is a growth hormone-releasing hormone analog studied in adults with HIV-associated abdominal lipohypertrophy.[2] The PinPoint library references prescribing information for its short half-life, subcutaneous route, and package amount.[1]

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
FDA-labeled presentation · 0.15 h model input

Editorial still life for peptides research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Tesamorelin library factsPeptides. Routes: subcutaneous. Half-life model input: 0.15 hours. Package: 2 mg / package. FDA-labeled presentation. CATEGORYROUTES IN LIBRARYHALF-LIFE MODEL INPUTTYPICAL PACKAGERESEARCH STATUS Peptidessubcutaneous0.15 hours2 mg / packageFDA-labeled presentation SOURCE / PINPOINT COMPOUND LIBRARY

Read the record in context

Tesamorelin is one of the entries with a labeled package reference rather than a supplier-only package citation. Even so, the 2 mg container total and the nine-minute model input are different facts. Neither number alone determines an amount to administer or a preparation method.[1]

What the research says

The Egrifta label describes two controlled studies in adults with HIV-associated lipodystrophy and excess abdominal fat. Participants received subcutaneous tesamorelin or placebo during a 26-week main phase. Eligibility included stable antiretroviral therapy and specified abdominal measurements, defining a particular clinical population.[2]

The primary outcome was change in visceral adipose tissue measured by computed tomography. Secondary assessments included body-image reports, lipid measures, IGF-1, and safety observations. The studies also tracked abdominal subcutaneous tissue, waist circumference, and body composition, distinguishing visceral fat from overall body weight.[2]

The label connects the newer formulation to earlier clinical studies through a bioavailability comparison. That formulation bridge matters because vial strength and administered exposure are not the same quantity. The guide preserves the labeled product context instead of treating every tesamorelin package as the material used in the original studies.[2]

Cited amounts

The library records 2 mg as a labeled package amount. This is the total listed in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[1][3]

Explore the Tesamorelin dosing chart

Half-life and timing

The 0.15-hour scalar translates to nine minutes. Two halvings occur after 18 minutes and four after 36 minutes, leaving 25% and 6.25% respectively. The five-half-life example ends at 45 minutes with 3.125% still modeled. This calculation isolates elimination arithmetic from absorption and from downstream hormone responses. The short axis does not imply that a physiological response shares the same duration, and it cannot turn a labeled vial total into a timing recommendation.[1][5]

Tesamorelin: modeled fraction over five half-livesStarting at 100 percent, the model halves each 0.15 hours. After 0.75 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%0.15 h50%0.3 h25%0.45 h12.5%0.6 h6.25%0.75 h3.125% Explore the Tesamorelin half-life model

Reconstitution

Taking the labeled 2 mg total and an explicitly hypothetical 2 mL final volume gives 1 mg/mL. In that constructed example, 0.1 mL corresponds to 0.1 mg, or 100 micrograms. The equality is a unit check, not a preparation method. A single-dose package description also does not authorize substituting an arbitrary water volume for the product's instructions. The guide uses the total to demonstrate the formula while leaving actual preparation and administration choices outside the calculation.[3]

2 mg ÷ 2 mL = 1 mg/mL
Open Tesamorelin conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]

The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

Does the tesamorelin vial amount establish the amount to administer?
The library's 2 mg figure is the total in a referenced single-dose vial. This guide does not infer an administration amount from that total. The calculator demonstrates concentration arithmetic only, using a stated hypothetical volume instead of providing preparation instructions.[1][2]
Is a tesamorelin single-dose vial total automatically the administered amount?
A package total describes supplied material. This page does not infer an administration amount from the label's 2 mg figure. The conversion example explicitly separates that sourced total from its hypothetical liquid-volume and portion-size inputs.[1][5]
Why display tesamorelin's half-life in both hours and minutes?
The app stores hours, while nine minutes makes a 0.15-hour interval easier to read. The two forms express the same input. They do not represent separate studies or add precision to the source by changing the unit.[1][5]
Can a peptide tracker app record Tesamorelin?
PinPoint's compound library includes Tesamorelin. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

  1. PinPoint compound library, TesamorelinSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
  2. DailyMed prescribing informationIdentity and research summary checked against this document on 5 October 2026. Clinical pharmacology and product-description sections.Retrieved 2026-10-05 · library-reference
  3. Labeled package referencePackage amount only; not a clinical amount or endorsement.Retrieved 2026-10-05 · label
  4. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
  5. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic